Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person BGT226 [cytosol]

Class:Id	ChemicalDrug:2399772
_displayName	BGT226 [cytosol]
_timestamp	2018-12-12 00:29:45
compartment	[Compartment:70101] cytosol
created	[InstanceEdit:2399727] Orlic-Milacic, M, 2012-07-12
crossReference	[DatabaseIdentifier:9628000] ChEBI:71953
disease	[Disease:1500689] cancer
literatureReference	[LiteratureReference:2399837] Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo
modified	[InstanceEdit:2457718] Orlic-Milacic, M, 2012-08-28 [InstanceEdit:3004607] Orlic-Milacic, M, 2013-01-29 [InstanceEdit:9016686] Orlic-Milacic, Marija, 2017-08-14 [InstanceEdit:9028147] Weiser, JD [InstanceEdit:9616752] Shorser, Solomon, 2018-08-13 [InstanceEdit:9619953] Wu, G, 2018-09-19 [InstanceEdit:9627975] Wu, G, 2018-11-05 [InstanceEdit:9631716] Wu, G, 2018-12-12
name	BGT226 NVP-BGT226
referenceEntity	[ReferenceTherapeutic:9016666] BGT-226 [Guide to Pharmacology:7951]
stableIdentifier	[StableIdentifier:2465043] R-ALL-2399772.2
(hasMember)	[CandidateSet:2399811] PI3K/mutant PI3K inhibitors [cytosol] [CandidateSet:9732428] PI3K inhibitors [cytosol]
[Change default viewing format]

No pathways have been reviewed or authored by BGT226 [cytosol] (2399772)